Navigation Links
Mederi Therapeutics Closes Funding of $18.5 Million
Date:12/23/2013

GREENWICH, Conn., Dec. 23, 2013 /PRNewswire/ -- Mederi Therapeutics Inc. announced today the closing on $18.5 million, comprised of Series B preferred stock and venture debt. Participating in this round were Acadia Woods Partners, LLC, Respiratory Diagnostics Inc., a subsidiary of Bio-Rad Laboratories, Inc., as well as a group of high net worth equity investors. Venture debt was provided by Horizon Technology Finance. The funds will be used to support and expand on the rapidly growing use of Mederi's Stretta therapy for Gastroesophageal Reflux Disease (GERD) and Secca therapy for Bowel Incontinence.

The overwhelming body of clinical data supporting Stretta's safety, efficacy and durability of effect has led to Mederi's rapid expansion. "Many device start-up companies launch with large sales forces and deep marketing budgets before gaining traction with clinical data and reimbursement. Mederi has strategically built sales and marketing as we gained such traction," said Will Rutan, CEO of Mederi. "This conservative approach has paid off, resulting in expanding insurance coverage domestically and abroad, significant growth in 2013, and product availability in almost 40 countries on a relatively small amount of investor capital."

"We are very pleased to have the support of all of our original investors plus a select new group, as well as the growing support of the medical community in our efforts to mainstream these safe and effective, minimally invasive therapies," continued Rutan.

The Value of a Safe, Effective, Low Cost Option
Mederi's radiofrequency treatments provide value to payers, providers and patients by offering safe, effective, durable and low-cost therapies.  Approximately 40 million Americans suffer from GERD, and 30% of those don't fully respond to medications. Stretta therapy for GERD is backed by more than 32 clinical studies showing up to 10 years of safe, durable symptom relief. These funds will allow Mederi to broaden Stretta's reach within the medical and patient communities, as it clearly addresses an unmet need in the treatment of GERD by providing an alternative to lifelong medications or surgery.

ABOUT MEDERI
Mederi Therapeutics manufactures and markets innovative medical devices that use radiofrequency energy to treat diseases of the digestive system, and holds over 80 patents in this technology. Mederi therapies — Stretta, for GERD and Secca, for Bowel Incontinence — have demonstrated clinical effectiveness in numerous studies; they are outpatient, minimally invasive and promote rapid recovery. Mederi is located in Greenwich, Connecticut. For more information visit www.mederi-inc.com.

Contact: Sheila Doyle, 203-930-9980, sdoyle@mederitherapeutics.com


'/>"/>
SOURCE Mederi Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. SkilaMederi and Qforma Announce Merger
2. SkilaMederi Names Ray Joske as Chief Commercial Officer
3. Aratana Therapeutics Provides 2013 Development Update
4. 2013 Report on the International Pain Management Therapeutics Market - Includes Forecast to 2018
5. Spark Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference
6. Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
7. Sorrento Therapeutics Completes Acquisition of Concortis Biosystems
8. Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics
9. Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders
10. Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
11. Halozyme Therapeutics Announces Executive Transitions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2017)... and LAGUNA HILLS, Calif. , ... of new data that validate the use of MMprofiler ... patients with multiple myeloma (MM). In a poster presentation ... Hematology Association (EHA) in Madrid, Spain ... MMprofiler for identifying high-risk elderly patients. ...
(Date:6/16/2017)... 50 years ago today, the Monterey Pop Festival opened its ... San Francisco "Summer of Love."  To celebrate the anniversary, Northern ... strategic market research portals that it will begin delivering to ... Light,s "Summer of Love (For Our Customers)."  ... Northern ...
(Date:6/13/2017)... , June 13, 2017 Zimmer Biomet Holdings, Inc. ... today announced that the U.S. Food and Drug Administration (FDA) ... 3, 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter ... manufacturing facility is a measure of the progress we have ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... June 25, 2017 , ... Republicans in the United States Senate on ... the Better Care Reconciliation Act. It differs significantly from the American Health Care Act, ... reconciled in committee, or the House will have to take up the Senate version ...
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the ... New Orleans. This is a new, greatly improved version of the Doctor Referral teaming ... requests by Fred Trotter and subsequently called the the “Doctor Referral Dataset” as released ...
(Date:6/25/2017)... ... June 25, 2017 , ... June is Men’s Health Month and the focus is ... among men in the U.S. and the third most common cause of cancer related death ... man in seven will be diagnosed with prostate cancer during his lifetime. Those at ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... Erie, PA at the Sheraton Erie Bayfront and Erie Convention Center on June ... medicine experience, exhibits, a student quiz bowl, award and scholarship presentations, and professional ...
(Date:6/24/2017)... ... , ... The weather is heating up and the days are getting longer, ... aware that the summer months provide more than warmer temperatures that are perfect for ... negatively affected from direct exposure to the sun. When it comes to the security ...
Breaking Medicine News(10 mins):